AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)

AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United StatesTherapy granted United States Food ...

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic ...

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ...
Multiple Sclerosis News Today

Myelin-targeting drug Lucid-MS inches closer to testing in patients

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

GH Research Shares Up, Plans to Provide Update on New Drug Application

Shares of GH Research rose on plans to provide an update on the status of its investigational new drug application for GH001, a therapy for treatment-resistant depression. The stock climbed 19% to $15 ...
TipRanks on MSN

Ascletis wins FDA green light for phase II US diabetes trial of oral GLP-1 drug ASC30

Ascletis Pharma, Inc. ( ($HK:1672) ) has provided an update. Ascletis Pharma has received U.S. FDA Investigational New Drug clearance to launch a ...

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...
Seeking Alpha

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, ...